Dexrazoxane Uses in Chemotherapy and Heart Protection

Dexrazoxane is the only drug approved by the U.S. Food and Drug Administration specifically to protect the heart from damage caused by anthracycline chemotherapy, a class of cancer drugs that includes doxorubicin, daunorubicin, and epirubicin. It also carries a separate FDA approval for treating anthracycline extravasation, the accidental leakage of these drugs out of a vein into surrounding tissue. These two uses make dexrazoxane an unusually focused drug: it exists almost entirely to manage the collateral damage of other treatments rather than to fight cancer directly. How well it works, who should receive it, and the safety debate that once limited its use are all worth understanding in detail.

Cardioprotection During Anthracycline Chemotherapy

Anthracyclines are among the most effective chemotherapy agents ever developed and remain a backbone of treatment for breast cancer, leukemias, lymphomas, and sarcomas. Their biggest long-term liability is heart damage. Anthracycline-related cardiotoxicity is dose-dependent and can show up as anything from subtle drops in heart-pumping function to full-blown congestive heart failure, sometimes years after treatment ends. Dexrazoxane was designed to blunt that damage.

In breast cancer, the evidence is strong. A pooled analysis of clinical trials found that dexrazoxane cut the risk of clinical heart failure by roughly 80 percent and reduced cardiac events overall by about two-thirds, regardless of how much anthracycline a patient had previously received.¹ That effect is large enough to change clinical decisions, particularly for patients who need higher cumulative doses of doxorubicin or who have pre-existing cardiac risk factors.

There is also case-series evidence that dexrazoxane can help patients who already have compromised hearts before starting chemotherapy. In a small consecutive series of adults with pre-existing cardiomyopathy who received dexrazoxane alongside anthracyclines, none developed symptomatic heart failure or showed elevated cardiac biomarkers during treatment.² That is a tiny dataset, but it hints at a population for whom the drug could be especially valuable.

How It Actually Protects the Heart

For decades, textbooks explained dexrazoxane’s benefit by saying that inside the body it breaks down into a compound called ADR-925, which chelates (binds up) free iron. The logic was tidy: anthracyclines generate toxic iron-driven free radicals in heart muscle cells, so removing the iron should reduce the damage. That explanation is now considered incomplete at best and probably wrong as the primary mechanism.

Research in cardiac cell models has shown that dexrazoxane works by interacting with an enzyme called topoisomerase IIβ (TOP2B) in heart cells. Anthracyclines hijack TOP2B to create DNA breaks in cardiomyocytes, and dexrazoxane prevents this by depleting the enzyme before the anthracycline arrives. In neonatal rat heart-cell experiments, dexrazoxane caused a rapid and near-complete loss of TOP2B protein, and its protective effect was greatest when TOP2B levels were at their lowest.³ A separate study went further, testing both dexrazoxane and the iron-chelating breakdown product ADR-925 head to head. Dexrazoxane inhibited and depleted TOP2B and prevented daunorubicin-induced DNA damage in heart cells; ADR-925 did not.⁴

This mechanistic shift matters beyond the lab. Understanding that the protection comes from TOP2B depletion rather than iron chelation has opened up research on related compounds that might be even better at the same job. One structural relative of dexrazoxane, a compound called ICRF-193, was found to inhibit and deplete TOP2B in cardiomyocytes more efficiently than dexrazoxane itself and showed higher cardioprotective potency in cell models.⁵ Whether that translates into a better drug for patients is unknown, but the mechanistic understanding makes the search for one more rational.

Children and Long-Term Heart Function

Pediatric oncology is where dexrazoxane’s long-term stakes are highest. A child cured of leukemia or lymphoma may live another 60 or 70 years with whatever cardiac damage the treatment caused. The case for cardioprotection here is not about surviving the next five years of treatment; it is about the quality of the next five decades.

An early randomized trial in children with acute lymphoblastic leukemia (ALL) showed that kids who received doxorubicin alone were substantially more likely to have elevated troponin T levels, a marker of heart muscle injury, compared to children who received dexrazoxane alongside the chemotherapy. Half the children in the doxorubicin-only group had elevated troponin T, versus about one in five in the dexrazoxane group.⁶

Longer follow-up has confirmed that those early biomarker differences translate into real cardiac function differences. Five years after doxorubicin treatment, children who received doxorubicin alone had measurably worse heart function on echocardiography compared to those who also received dexrazoxane. The protective effect on heart wall thickness and the ratio of wall thickness to chamber size remained statistically significant at five years. Interestingly, the long-term cardiac benefit appeared greater in girls than in boys, though the reasons for that sex difference are not fully understood.⁷ Event-free survival was virtually identical between the two groups, at 77 percent versus 76 percent, meaning the heart protection did not come at the cost of cancer control.⁸

Even further out, a large study of childhood cancer survivors assessed heart function a median of roughly 18 years after treatment. Dexrazoxane recipients had better left ventricular pumping (both fractional shortening and ejection fraction) and lower levels of B-type natriuretic peptide, a blood marker of cardiac stress. Those who received dexrazoxane were about 75 percent less likely to have reduced heart function below clinical thresholds, and this benefit was most prominent in patients who had received cumulative doxorubicin doses of 250 mg/m² or more.⁹ A separate echocardiographic follow-up study of adult survivors who had been treated as children with dexrazoxane and anthracyclines found no evidence of cardiac toxicity by current guideline criteria, with standard heart-function measurements indistinguishable from healthy controls.¹⁰

Treating Anthracycline Extravasation

Dexrazoxane’s second approved use is less well known but clinically dramatic. When an anthracycline leaks out of a vein during infusion, it can cause severe tissue necrosis, potentially requiring surgical removal of damaged skin and underlying tissue. Before dexrazoxane’s approval for this indication, treatment options were limited to cold compresses, topical DMSO, and, often, surgery. In 2007, the FDA approved an intravenous formulation of dexrazoxane specifically for extravasation rescue, given as a three-day course starting within six hours of the event.¹¹

The approval data came from two studies totaling 57 patients with confirmed anthracycline extravasation. Only one of those patients ultimately needed surgical repair. Late complications in the rest were absent or mild.¹² Preclinical work in mice had shown that a single dose of dexrazoxane given immediately after subcutaneous anthracycline injection could reduce tissue damage by as much as 96 percent for doxorubicin, 87 percent for idarubicin, and 70 percent for daunorubicin.¹³ The mechanism here likely involves both TOP2B inhibition in the affected tissue and some degree of iron chelation, though the relative contributions remain debated.

The Secondary Malignancy Debate

No discussion of dexrazoxane is honest without addressing the safety concern that almost derailed its use in children. In the mid-2000s, a pediatric Hodgkin’s disease trial reported a numerically higher rate of secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in children who received dexrazoxane. The four-year cumulative incidence of secondary AML/MDS was about 2.6 percent in the dexrazoxane group versus roughly 0.9 percent without it, though this difference did not reach statistical significance.¹⁴ That finding triggered significant regulatory caution: the European Medicines Agency initially contraindicated dexrazoxane in children entirely.

Subsequent larger analyses have not confirmed the concern. A study pooling data from over 15,000 pediatric oncology patients found that the secondary AML rate was actually numerically lower in dexrazoxane-exposed children (0.21 percent) than in unexposed children (0.55 percent), and propensity-adjusted analysis showed no increased risk.¹⁵ A Children’s Oncology Group report on late mortality found no difference in overall survival at ten years between children who did and did not receive dexrazoxane, with hazard ratios near 1.0 for death from any cause, death from the original cancer, and death from second cancers.¹⁶ With even longer follow-up, extending to a median of nearly 19 years, dexrazoxane was still not associated with increased relapse, second cancers, all-cause mortality, or cardiovascular mortality across randomized trials.¹⁷

In 2017, the EMA reversed its earlier stance. After reviewing accumulated safety data, it concluded that dexrazoxane should no longer be contraindicated in children at the highest risk of cardiotoxicity and found no data supporting an association with increased second primary malignancies, interference with chemotherapy, or increased risk of early death in children.¹⁸ The updated guidance effectively allows nearly all children receiving anthracyclines to receive dexrazoxane starting from the first dose, at the treating physician’s discretion.¹⁹

Side Effects to Expect

Dexrazoxane is not side-effect free. The most consistent finding across studies is that it increases bone marrow suppression when added to anthracycline regimens. In a study of soft-tissue sarcoma patients receiving anthracycline-based chemotherapy with or without dexrazoxane, the addition of the cardioprotectant was associated with substantially higher rates of severe blood count drops: severe low white blood cell counts occurred in roughly 57 percent of dexrazoxane-treated patients compared with 29 percent without it, severe low neutrophil counts in 70 percent versus 24 percent, and febrile neutropenia (a dangerous combination of low neutrophils and fever) in 52 percent versus 21 percent. Low platelet counts were also more common.²⁰ Dose reductions of the chemotherapy itself were twice as frequent in the dexrazoxane group.²¹

This means that adding dexrazoxane is a tradeoff: you are protecting the heart at the cost of deeper blood count drops, more infections, and sometimes having to reduce the chemotherapy dose. For most patients the math still favors cardioprotection, but it is a calculation that depends on the specific cancer being treated, the patient’s baseline blood counts, and how much anthracycline is planned.

How It Is Given

Dexrazoxane is administered as a 15-minute intravenous infusion, typically given 30 minutes to an hour before the anthracycline. The standard dosing ratio is 10:1 relative to doxorubicin, so a patient receiving 50 mg/m² of doxorubicin would receive 500 mg/m² of dexrazoxane. In patients with significantly impaired kidney function (creatinine clearance below 40 mL/min), the dose is cut in half, bringing the ratio to 5:1. For patients with liver impairment, the dexrazoxane dose is reduced in step with doxorubicin to maintain the same 10:1 proportion.²²

The timing and infusion rate matter. A rapid bolus push is not recommended; the 15-minute infusion window appears to improve tolerability. For extravasation treatment, the dosing schedule is different: a three-day intravenous regimen starting within six hours of the extravasation event.²³

How Dexrazoxane Compares to Other Cardioprotective Approaches

Dexrazoxane is not the only strategy clinicians use to protect the heart during anthracycline therapy. Beta-blockers and other heart medications are sometimes prescribed alongside chemotherapy. A recent systematic review and meta-analysis of randomized trials in breast cancer compared several approaches and found that dexrazoxane outperformed beta-blockers in preserving heart function. Mineralocorticoid receptor antagonists (drugs like spironolactone or eplerenone) actually outperformed both in the analysis, though the authors noted greater uncertainty in the dexrazoxane data.²⁴

Other strategies that oncologists use include limiting the cumulative anthracycline dose, switching to liposomal formulations of doxorubicin, and using continuous infusion rather than bolus dosing. None of these are mutually exclusive with dexrazoxane. In practice, many patients receive dexrazoxane as part of a broader cardioprotective plan that includes monitoring, dose management, and sometimes concurrent heart medications.

Cost-Effectiveness

Adding a drug to a chemotherapy regimen always raises cost questions. In pediatric oncology, a European analysis across five countries found that dexrazoxane was cost-effective for children receiving anthracyclines for sarcoma and blood cancers, regardless of the cumulative anthracycline dose received. Treated patients gained on average between 0.5 and 0.7 quality-adjusted life years (QALYs), a measure that accounts for both length and quality of life. In some countries like Spain and Italy, dexrazoxane was actually cost-saving overall, meaning the savings from prevented cardiac events more than offset the drug cost. In the UK and Germany, the cost per QALY gained was still well below standard thresholds for what health systems consider worthwhile.²⁵

An older pharmacoeconomic model in adults with metastatic breast cancer calculated the cost at roughly $5,662 per cardiac event prevented, a figure that held steady across sensitivity analyses adjusting the model’s assumptions.²⁶ That study is from the late 1990s and the absolute dollar figures are dated, but the general finding that preventing heart failure is cheaper than treating it has only strengthened with time.

Experimental Uses Beyond Chemotherapy

Radiation therapy can also injure the heart, particularly for cancers of the chest such as breast cancer, lung cancer, and lymphomas. Radiation-induced heart disease is a growing concern as cancer survivors live longer and their latent cardiac injuries start to surface. In a rat model, dexrazoxane given alongside radiation suppressed heart cell death and reversed radiation-induced elevations in cardiac troponin I levels. Tissue examination six months after radiation showed better preservation of heart structure in dexrazoxane-treated animals, with the benefit attributed to suppression of both programmed cell death and oxidative stress.²⁷ This is animal data only, and no human trials have yet tested dexrazoxane for radiation-induced cardiac protection. But given that the drug is already approved, widely available, and has a known safety profile, it is a logical candidate for clinical study in this setting.